Investigational Study of an NVG-291-Designated Peptide with Thymosin Beta-4 (TB-4) in Complete Spinal Cord Injury: Clinical Outcomes Over a 12-Month Follow-Up
The combination of NVG-291 and thymosin beta-4 showed greater improvements in motor function and walking ability in individuals with complete spinal cord injury compared to placebo over 12 months.
Where it sits
this study against the rest of the thymosin beta-4 (tβ4) corpusSummary and findings
This study evaluated the effects of a combination of NVG-291 and thymosin beta-4 (TB-4) on motor and functional outcomes in 30 participants with complete spinal cord injury over 12 months. Participants received either the combination treatment or a saline placebo, both alongside a conservative rehabilitation program. The combination treatment showed greater improvements in motor scores and walking ability compared to placebo.
Abstract
<h4>Background: </h4> Restoring useful motor function remains a major unmet need after complete spinal cord injury (SCI). A PTPσ-targeting peptide designated NVG-291, which relieves proteoglycan-mediated inhibition of axonal growth, and thymosin beta-4 (TB-4), which has cytoprotective and anti-inflammatory actions, offer complementary mechanisms that may enhance the response to rehabilitation. <h4>Objective:</h4> To evaluate 12-month motor and functional outcomes of the investigator-initiated NuRaX combination protocol (NVG-291 plus TB-4) compared with placebo, each added to conservative rehabilitation. <h4>Methods:</h4> In this single-center, randomized, double-blind, placebo-controlled study conducted at the NuRaX Center in partnership with Ege Hospital in Baku, Azerbaijan, 30 participants with complete (AIS A) SCI were assigned in a 1:1 ratio to the combination protocol (n = 15) or saline placebo (n = 15). Combination treatment comprised NVG-291 2.5 mg and TB-4 1.5 mg subcutaneously every 14 days for 12 months (cumulative 65 mg and 39 mg, respectively), plus a single 3.5 mg paraspinal NVG-291 dose at the T11–T12 vertebral level; placebo injections were matched in volume, route and timing. Both groups received the same rehabilitation program without stimulation or robotic equipment. Outcomes included lower extremity motor score (LEMS), walker-supported standing duration and 100-m walking completion without orthoses or physical assistance. All assessments were independently re-screened by blinded external consultants. <h4>Results:</h4> Mean LEMS increased by 7.6 points with combination treatment and by 0.6 points with placebo (between-group difference, 7.0 points; 95% CI, 4.8 to 9.2); the baseline-adjusted difference was 7.39 points (95% CI, 5.86 to 8.92). Standing duration increased by 4.01 minutes more with combination treatment (95% CI, 2.37 to 5.65). At 12 months, 13 of 15 combination participants (86.7%) and 1 of 15 placebo participants (6.7%) completed 100 m with a walker, without orthoses or physical assistance. No AIS grade conversion or change in bladder or bowel function was reported. No adverse events or injection-site reactions were documented. <h4>Conclusions:</h4> In participants with complete SCI, the NuRaX combination of NVG-291 and TB-4 added to conservative rehabilitation was associated with greater improvement in lower-limb motor scores, standing endurance and walker-supported walking than placebo with the same rehabilitation over 12 months. These findings support further evaluation in larger, prospectively registered, randomized trials.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.